

CardioComm Solutions Inc. Corporate Update

VICTORIA, B.C., August 29, 2007 – CardioComm Solutions Inc. (TSX-V:CCG) ("CardioComm", the "Company"), is pleased to provide a Corporate update as follows:

- CardioComm will launch GlobalCardio 12 Lead ECG web based system commencing in September 2007. CardioComm's model is to provide a 12 lead ECG device to physicians along with access to GlobalCardio 12 Lead to allow physicians to provide ECGs for patients in clinic in an effective low cost transaction based method. This system will revolutionize basic cardiac care in physician's offices. The system has been successfully trialed in four cardiology clinics for eight months and two family practices for two months.
- CardioComm has been engaged by the Canadian Heart Research Centre to provide ECG services in family physicians offices participating in one of the largest outpatient atrial fibrillation studies in Canada. This is further support for GlobalCardio 12 Lead system.
- CardioComm has secured a development contract for \$250,000 related to further 12 lead development
- CardioComm continues to streamline operations and refocusing business development activities looking forward to the launch of GlobalCardio 12 Lead
- The financial statements and Management Discussion and Analysis for the period ending June 30, 2007 have been filed today and are available at www.sedar.com

About CardioComm Solutions Inc.

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMST[™]) and GlobalCardio[™]. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions Inc.

"Stephen Martin"

Stephen R. Martin, President & CEO

For investor information, please contact:

Stephen Martin

1-877-744-1122

ir@cardiocomm.com

*The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release*